CGC stock forecast, quote, news & analysis
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada... Show more
Why Canopy Growth (CGC) Stock Is Down -27% in the Last 30 Days
Key Takeaways
- Canopy Growth shares declined roughly 27% over the past 30 days, sliding from about $0.93 to near $0.67.
- A Nasdaq minimum bid price deficiency notice and a newly authorized share consolidation framed the selloff.
- Over the last quarter, the stock is down approximately 25% after peaking near $1.07 in late August.
- Slower-than-expected U.S. cannabis rescheduling and persistent share dilution concerns continue to pressure sentiment.
- The company is scheduled to report fiscal second-quarter 2027 results on November 6, 2026, a key near-term catalyst.
- For additional context, explore Canopy Growth's Price Targets, Earnings, and Forecast pages.
- For automated trading ideas across the market, explore Trending AI Robots.
Canopy Growth (CGC) Company Overview and Market Position
Canopy Growth Corporation is a Canadian cannabis company headquartered in Smiths Falls, Ontario. The company cultivates, processes, and distributes cannabis for both medical and adult-use markets, with a portfolio that includes dried flower, pre-rolls, oils, softgels, vapes, beverages, and edibles. Its brand lineup includes Tweed, 7ACRES, DOJA, Deep Space, and MTL Cannabis, while its Storz & Bickel unit produces premium vaporizers such as the Volcano and Mighty.
Beyond Canada, Canopy Growth operates in select international medical-cannabis markets and holds an unconsolidated, non-controlling interest in Canopy USA, which provides exposure to U.S. state-licensed assets. Investors follow the stock closely because of its history as one of the sector's largest listed producers, its restructuring toward a leaner cost base, and its long-standing positioning for potential U.S. federal cannabis reform.
Canopy Growth (CGC) Stock Price Performance: Last 30 Days vs. Quarter
Over the past 30 days, CGC shares fell from a closing price near $0.93 to approximately $0.67, a decline of about 27%. The move accelerated through October as the stock broke below the $1.00 threshold and then the $0.80 level.
The broader three-month picture tells a similar story of reversal. After rallying through the summer to a peak near $1.07 in late August, the stock gave back its gains and ended the quarter roughly 25% lower. This pattern reflects an initial lift tied to optimism around U.S. cannabis rescheduling, followed by a steady unwind as regulatory progress stalled and company-specific concerns resurfaced.
What Drove CGC Stock Price in the Last 30 Days
The most significant catalyst was regulatory and listing-related. On October 14, 2026, Canopy Growth disclosed in a securities filing that Nasdaq had notified the company it was not in compliance with Listing Rule 5450(a)(1) because its shares had closed below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 calendar days, until April 12, 2027, to regain compliance.
Compounding that news, shareholders at the reconvened annual meeting on October 23, 2026 approved a share consolidation authorization, allowing the board to implement a reverse split at a ratio between one-for-five and one-for-fifteen before October 23, 2027. While the consolidation has not yet been implemented, the proposal reinforced concerns about the stock's sub-$1 trading range and the company's capital structure.
Broader cannabis-sector dynamics also weighed on the shares. Progress on U.S. federal rescheduling remained stalled, dampening the reform-driven optimism that had lifted the stock earlier in the year. Persistent share dilution, with the share count having risen significantly over the prior year, added further downward pressure, alongside a proposed Canadian securities class action settlement that kept the company in the headlines.
What Drove CGC Stock Performance Over the Last Quarter
The quarterly trend was defined by an unwinding of reform enthusiasm. Earlier in 2026, the U.S. Department of Justice and Drug Enforcement Administration moved to reschedule medical cannabis from Schedule I to Schedule III, sparking a rally in cannabis equities. Canopy Growth's U.S.-focused structure made it a direct beneficiary of that sentiment, helping the stock climb toward $1.07 by late August.
However, further regulatory movement failed to materialize, and the market's focus shifted back to fundamentals. Although the company's fiscal 2027 first-quarter results reported in August showed higher revenue, improved gross margins, and narrower losses, investors remained concerned about the pace of the turnaround, continued reliance on equity capital, and the lack of clarity on U.S. market access. Those concerns ultimately outweighed the operational improvements, driving the stock lower through September and October.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots drawn from a platform that operates hundreds of bots trading thousands of tickers. Rather than listing every available strategy, the page surfaces the top-performing and most relevant bots, each with distinct strategies, timeframes, and performance metrics. Traders can review how these automated systems approach markets, from short-term momentum to longer-horizon positioning, and assess which align with their own objectives. For investors monitoring volatile names such as CGC, exploring these tools can offer additional perspective on systematic approaches to price action.
CGC Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor several near-term factors. The company's fiscal second-quarter 2027 results, scheduled for November 6, 2026, will provide updated insight into revenue trends, gross margins, and progress toward management's profitability goals. Commentary on international medical-cannabis growth and the Canadian consumer market will also be closely watched.
The Nasdaq compliance timeline remains a central issue, with the company needing to restore a bid price at or above $1.00 for at least ten consecutive business days or pursue a reverse split. Any decision to implement the authorized share consolidation would alter the share structure. Finally, the pace of U.S. federal cannabis rescheduling and any developments around Canopy USA will continue to influence sentiment, alongside broader dilution and capital-raising activity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CGC's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for CGC turned positive on November 02, 2026. Looking at past instances where CGC's MACD turned positive, the stock continued to rise in 35 of 40 cases over the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for CGC's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +10.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGC advanced for three days, in 162 of 199 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CGC may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 06, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CGC as a result. In 74 of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CGC entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.400) is normal, around the industry mean (6.379). P/E Ratio (-0.972) is within average values for comparable stocks, (0.548). CGC's Projected Growth (PEG Ratio) (7.200) is slightly higher than the industry average of (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.549) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. CGC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of medical marijuana
Industry PharmaceuticalsGeneric